Oslo, Norway, April 21, 2021 - Vaccibody AS, a clinical-stage biopharmaceutical
company dedicated to the discovery and development of vaccines and novel
immunotherapies, announced that the Board of Directors has approved the
Company's financial statements for 2020.

The Company's annual accounts for the financial year 2020, including the
financial statements and annual report, are together with the auditor's report
attached to this announcement. Vaccibody's annual report 2020 contains the first
annual accounts where the financial statements have been prepared in accordance
with IFRS (International Financial Reporting Standards). The financial
statements are presented in United States dollar (USD). The annual report 2020
is also available at the Company's website, http://www.vaccibody.com

About Vaccibody
Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the
discovery and development of vaccines and novel immunotherapies. The Company
develops vaccines for the treatment cancer and infectious diseases. Vaccibody's
vaccine technology specifically targets antigens to Antigen Presenting Cells,
which are essential for inducing rapid, strong and long-lasting antigen-specific
immune responses and elicit efficacious clinical responses. Its lead product
candidates include VB10.NEO, a cancer neoantigen vaccine, which is exclusively
outlicensed to Genentech and is in phase I/IIa clinical trial for the treatment
of melanoma, lung-, head and neck, renal-, and bladder cancer